Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Orthocell Moves Closer to UK Growth Orthocell (ASX: OCC) just made a move that not every small-cap medtech company would make. Rather than waiting for regulatory approval before signing a…

ByUjjwal Maheshwari

11

Dec 2025

Healthcare Stocks

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Orthocell (ASX: OCC) jumped 7% to A$1.09 on Wednesday after announcing its first commercial sales of Remplir in Hong Kong. The sales, made through distributor MontsMed, follow last month's first…

ByUjjwal Maheshwari

04

Apr 2025

Biotech Stocks Healthcare Stocks

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in Australia, New Zealand and Singapore, plus approval is pending in…

ByNick Sundich

15

Oct 2024

Healthcare Stocks Life Sciences

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why. For many companies, the golden market has been the USA,…

ByNick Sundich

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here